News
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback